Home Cart Sign in  
Chemical Structure| 64924-67-0 Chemical Structure| 64924-67-0

Structure of Halofuginone hydrobromide
CAS No.: 64924-67-0

Chemical Structure| 64924-67-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Halofuginone hydrobromide ointment may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.

Synonyms: RU-19110 hydrobromide; Halofuginone(hydrobromide)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Halofuginone hydrobromide

CAS No. :64924-67-0
Formula : C16H18Br2ClN3O3
M.W : 495.59
SMILES Code : O=C1N(CC(C[C@H]2NCCC[C@@H]2O)=O)C=NC3=C1C=C(Cl)C(Br)=C3.[H]Br
Synonyms :
RU-19110 hydrobromide; Halofuginone(hydrobromide)
MDL No. :MFCD00946455

Safety of Halofuginone hydrobromide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Halofuginone hydrobromide

DNA

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01978366 Duchenne Muscular Dystrophy Phase 2 Terminated(Dosing stopped) - United States, California ... More >> University of California, Davis Medical Center Sacramento, California, United States, 95817 United States, Maryland Kennedy Krieger Institute, Johns Hopkins School of Medicine Baltimore, Maryland, United States, 21205 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 Less <<
NCT00027677 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - Belgium ... More >> U.Z. Gasthuisberg Leuven, Belgium, B-3000 Netherlands University Hospital - Rotterdam Dijkzigt Rotterdam, Netherlands, 3000 CA Daniel Den Hoed Cancer Center at Erasmus Medical Center Rotterdam, Netherlands, 3008 AE Less <<
NCT02525302 Duchenne Muscular Dystrophy Phase 2 Terminated(Dosing stopped) - United States, California ... More >> University of California, Davis Medical Center Sacramento, California, United States, 95817 United States, Maryland Kennedy Krieger Institute, Johns Hopkins School of Medicine Baltimore, Maryland, United States, 21205 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 Less <<
NCT00064142 AIDS-related Kaposi Sarcoma ... More >> Recurrent Kaposi Sarcoma Less << Phase 2 Completed - United States, Maryland ... More >> AIDS - Associated Malignancies Clinical Trials Consortium Rockville, Maryland, United States, 20850 Less <<
NCT01847573 Duchenne Muscular Dystrophy Phase 1 Phase 2 Terminated(Dosing stopped) - United States, California ... More >> University of California, Davis Medical Center Sacramento, California, United States, 95817 United States, Maryland Kennedy Krieger Institute, Johns Hopkins School of Medicine Baltimore, Maryland, United States, 21205 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.02mL

0.40mL

0.20mL

10.09mL

2.02mL

1.01mL

20.18mL

4.04mL

2.02mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories